Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer

Clinical Pharmacokinetics

Volumn 37, Issue 3, 1999, Pages 195-211

  Danesi, Romano ^a   Conte, Pier Franco ^b   Del Tacca, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CREMOPHOR; CYCLOSPORIN; DOXORUBICIN; EPIRUBICIN; EPIRUBICINOL; GLYCOPROTEIN P; PACLITAXEL;

AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; DRUG STRUCTURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; NEUTROPHIL; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PACLITAXEL; TIME FACTORS;

EID: 0032873140     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199937030-00002     Document Type: Review

References (62)

1. Eisenhauer EA, Vermorken JB. The taxoids: comparative clinical pharmacology and therapeutic potential. Drugs 1998 Jan; 55 (1): 5-30
2. Mamounas E, Brown A, Smith R, et al. Effect of taxol duration of infusion in advanced breast cancer: results from NSABP B-26 trial comparing 3- to 24-hr infusion of high-dose taxol [abstract no. 389]. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 101
3. Coukell AJ, Faulds D. Epirubicin: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Drugs 1997 Mar; 53 (3): 453-82
4. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995 Nov; 13 (11): 2688-99
5. Dombernowsky P, Gehl J, Boesgaard M, et al. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 1996 Feb; 23 (1 Suppl. 1): 13-8
6. Conte PF. Baldini E, Gennari A, et al. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 1997 Jul; 15 (7): 2510-7
7. Miller KD, Sledge Jr GW. Taxanes in the treatment of breast cancer: a prodigy comes of age. Cancer Invest 1999; 17 (2): 121-36
8. Henderson IC, Berry D, Demetri G, et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node positive primary breast cancer [abstract no. 390A]. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 101a
9. Hudis C, Riccio L, Seidman A, et al. Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel. Cancer Invest 1998; 16 (2): 67-71
10. Wiseman LR, Spencer CM. Paclitaxel: an update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging 1908 Apr: 12 (4): 305-34
11. Akutsu M, Kano Y, Tsunoda S, et al. Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro. Eur J Cancer 1995 Dec; 31A (13-14): 2341-6
12. Zoli W, Ricotti L, Barzanti F, et al. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer 1999 Jan 29; 80 (3): 413-6
13. Hahn SM, Liebmann JE, Cook J, et al. Taxol in combination with doxorubicin or ctoposide. Possible antagonism in vitro. Cancer 1993 Nov 1; 72 (9): 2705-11
14. Mechetner E, Kyshtoobayeva A, Zonis S, et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 1998 Feb; 4 (2): 389-98
15. Gianni L, Vigano L, Locatelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997 May; 15 (5): 1906-15
16. Marks DC, Su GM, Davey RA, et al. Extended multidrug resistance in haemopoietic cells. Br J Haematol 1996 Dec; 95 (4): 587-95
17. Su GM, Davey MW, Davey RA. Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel. Int J Cancer 1998 May 29; 76 (5): 702-8
18. Brouty-Boye D, Kolonias D, Lampidis TJ. Antiproliferative activity of taxol on human tumor and normal breast cells vs. effects on cardiac cells. Int J Cancer 1995 Feb 8; 60 (4): 571-5
19. Decorti G, Candussio L, Klugmann FB, et al. Adriamycin-induced histamine release from heart tissue in vitro. Cancer Chemother Pharmacol 1997; 40 (4): 363-6
20. Mushlin PS, Cusack BJ, Boucek Jr RJ, et al. Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol 1993 Nov; 110 (3): 975-82
21. Minotti G, Cavaliere AF, Mordente A, et al. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline Metabolism and iron-induced cardiotoxicity. J Clin Invest 1995 Apr; 95 (4): 1595-605
22. Kumar G, Ray S, Walle T, et al. Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6α-hydroxytaxol. Cancer Chemother Pharmacol 1995; 36 (2): 129-35
23. Raymond E, Faivre E, Izbicka E, et al. Comparison of prolonged and short term exposure paclitaxel (Taxol) using the human tumor cloning assay [abstract no. 351]. 10th NCI EORTC Symposium on New Drugs in Cancer Therapy; 1998 Jun 16-19: Amsterdam, Ann Oncol 1998 Oct; 9 Suppl. 2: 92
24. Raymond E, Faivre E, Izbicka E, et al. Comparison of prolonged and short term exposure paclitaxel (Taxol) using the human tumor cloning assay [abstract no. 351]. 10th NCI EORTC Symposium on New Drugs in Cancer Therapy; 1998 Jun 16-19: Amsterdam, Ann Oncol 1998 Oct; 9 Suppl. 2: 92
25. Nicholson KM, Bibby MC, Phillips RM. Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. Eur J Cancer 1997 Jul; 33 (8): 1291-8
26. Danesi R, Figg WD, Reed E, et al. Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol 1995 Jun; 47 (6): 1106-11
27. Colombo T, Gonzalez Paz O, Zucchetti M, et al. Paclitaxel induces significant changes in epidoxorubicin distribution in mice. Ann Oncol 1996 Oct; 7 (8): 801-5
28. Webster LK, Cosson EJ, Stokes KH, et al. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 1996 Feb; 73 (4): 522-4
29. Sparreboom A, van Tellingen O, Nooijen WJ, et al. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996 May 1; 56 (9): 2112-5
30. Cividalli A, Cruciani G, Livdi E, et al. Greater antitumor efficacy of puclitaxel administered before epirubicin in a mouse mammary carcinoma. J Cancer Res Clin Oncol 1998; 124 (5): 236-44
31. Berg LB, Cowan KH, Balis FM, et al. Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 1994 Jan 19; 86 (2): 143-5
32. Fisherman JS, Cowan KH, Noone M, et al. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol 1996 Mar; 14 (3): 774-82
33. Holmes FA, Madden T, Newman RA, et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer, J Clin Oncol 1996 Oct; 14 (10): 2713-21
34. Danesi R, Innocenti F, Fogli S, et al. Pharmacokinetics and metabolic interaction of paclitaxel, epirubicin and epirubicinol in advanced breast cancer patients. Clin Pharmacol Ther. In press
35. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance, J Clin Oncol 1994 Apr; 12 (4): 835-42
36. Panday VR, Huizing MT, Willemse PH, et al. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin Oncol 1997 Aug; 24 (4 Suppl. 11): S1134-8
37. Donelli MG, Zucchetti M, Munzone E, et al. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998 Jan; 34 (1): 33-46
38. Rahman A, Korzekwa KR, Grogan J, et al. Selective biotransformation of taxol to 6-alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1904 Nov 1; 54 (21): 5543-6
39. Monsarrat B, Royer I, Wright M, et al. Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. Bull Cancer 1997 Feb; 84 (2): 125-33
40. Huizing MT, Vermorken JB, Rosing H, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol 1995 Sep; 6 (7): 699-704
41. Sonnichsen DS, Lin Q, Schuetz EG, et al. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995 Nov; 275 (2): 566-75
42. Fischer V, Rodriguez-Gascon A, Heitz F, et al. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A: implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 1998 Aug 1; 26 (8): 802-11
43. Royer I, Monsarrat B, Sonnier M, et al. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996 Jan; 56 (1): 58-65
44. Marre F, Sanderink G-J, de Sousa G, et al. Hepatic biotransformation of docetzxel (Taxotere®) in vitro; involvement of the CYP3A subfamily in humans. Cancer Res 1906 Mar 15; 56 (6): 1296-302
45. Desai PB, Duan JZ, Zhu YW, et al. human liver mircosomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 1998 Jul-Sep; 23 (3): 417-24
46. Kumar GN, Walle UK, Walle T. Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J Pharmacol Exp Ther 1904 Mar; 268 (3): 1160-5
47. Harris JW, Rahman A, Kim BR, et al. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994 Aug 1; 54 (15): 4026-35
48. Cresteil T, Monsarrat B, Alvinerie P, et al. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994 Jan 15; 54 (2): 386-92
49. Chang SM, Kuhn JG, Rizzo J, et al. Phase 1 study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 1998 Jun; 16 (6): 2188-94
50. Esposito M, Venturini M, Vannozzi MO, et al. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. J Clin Oncol 1999 Apr; 17 (4): 1132-40
51. Monsarrat B, Alvineric P, Wright M, et al. Hepatic metabolism and biliary excretion of Taxol in rats and humans. J Natl Cancer Inst Monogr 1993; 15: 39-46
52. Sikic BI, Fisher GA, Lum BL, et al. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997; 40 Suppl.: S13-9
53. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 1998 May; 16 (5): 1811-9
54. Twelves CJ, Dobbs NA, Gillies HC, et al. Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests. Cancer Chemother Pharmacol 1998; 42 (3): 229-34
55. Twelves CJ, Dobbs NA, Michael Y, et al. Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. Br J Cancer 1992; 66 (4): 765-9
56. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995 Jan; 13 (1): 180-90
57. Huizing MT, Giaccone G, van Warmerdam LJC, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small cell lung cancer. J Clin Oncol 1997 Jan; 15 (1): 317-29
58. Beijnen JH, Huizing MT, ten Bokkel Huinink WW, et al. Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol). Semin Oncol 1994 Oct; 21 (5 Suppl. 8): 53-62
59. Hon YY, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 1998 Feb; 44 (2): 388-400
60. Hortobagyi GN, Holmes FA. Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer. Semin Oncol 1997 Feb; 24 (1 Suppl. 3): S4-7
61. Baker SD. Drug interactions with the taxanes. Pharmacotherapy 1997 Sep; 17(5 Pt 2): 126-32S
62. Amadori D, Frassinetti GL, Zoli W, et al. A phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer. Semin Oncol 1996 Feb; 23 (1 Suppl. 1): 19-23